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Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease mostly due to smoking and until 
now diagnosed by spirometry (post bronchodilator FEV1/FVC <70%). However, in spite of the usefulness of FEV1 as 
diagnostic and prognostic tool, it has proven to be a weak indicator of future exacerbations, unable to predict lung func-
tion decline within COPD patients, as well as unable to identify the smokers “susceptible” to developing COPD at an 
early stage. Thus, there is an urgent need for biomarkers that address these questions and support clinical decision mak-
ing in the diagnosis and treatment of (early) COPD. In this respect, considerable efforts have been devoted to identify-
ing protein biomarkers that enable a better understanding of this complex disease and leading to better diagnostic and 
prognostic tools. However, in spite of the wide range of candidates that have been suggested as potentially useful COPD 
biomarkers, most remained at the level of the initial discovery, and only fibrinogen has been approved by the Food and 
Drug Administration (FDA) as predictor for all-cause mortality and COPD exacerbations. There is thus a need for future 
investigations of these biomarkers in large-scale and well characterized studies in order to prove their usefulness as 
surrogate endpoints. Based on this, the aim of the present review is to advance COPD biomarker development by pro-
viding a comprehensive overview of protein biomarker candidates which have been evaluated in clinical studies and 
prioritize them according to their potential of becoming valid, clinically useful COPD biomarkers. 
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Introduction 
hronic obstructive pulmonary disease (COPD) 
is defined as a ‘common preventable and trea-
table disease that is characterized by persistent 
airflow limitation that is usually progressive and asso-
ciated with an enhanced chronic inflammatory res-
ponse in the airways and the lung to noxious particles 
or gases’[1]. COPD is an umbrella term that covers 
several pathological conditions and has many clinical 
and pathological phenotypes[2]. Examples of such  
phenotypes are chronic bronchitis, emphysema, chr-
onic mucus hypersecretion and small airways thick-
ening. Besides encompassing pulmonary components, 
this term also covers additional features such as ex-
acerbations and comorbidities, since COPD is recog-
nized as a complex and multicomponent syndrome 
with both pulmonary and extrapulmonary manifesta-
tions[1,3–5]. The forced expiratory volume in 1 second 
(FEV1) is the current “gold standard” marker of dis-
ease progression, response to therapy, and prediction 
of mortality[6]. Unfortunately, it has proven to be a 
weak indicator of future exacerbations, unable to pre-
dict lung function decline as well as ineffective for  
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developing treatment regimens that can significantly 
reduce mortality rates or alter the disease course[2,7]. 
For this reason, there has been a growing interest in 
discovering new biomarkers that would allow a better 
understanding of this heterogeneous and complex 
disease[4,8,9]. Interesting challenges in current COPD 
medicine include developing tools that allow optimiz-
ing therapeutic interventions following the shift of a 
general COPD treatment towards a more personalized, 
patient-centered medicine[10,11]. For example, bio-
markers that would support decisions such as the use 
of bronchodilators and/or inhaled corticosteroids[12–14], 
are of outmost interest in order to select the most 
adequate treatment option for each patient[11]. Further-
more, the prediction of lung function decline amongst 
COPD patients and therefore development of bio-
markers that enable differentiation of slow and fast 
decliners, would be of importance in developing early 
stage treatments for particularly the fast decliners as 
well as in understanding the mechanisms that are in-
volved in the progression and severity of COPD[15–19]. 
In this respect, it is important to mention that only a 
small proportion (20–30%) of smokers develop COPD, 
suggesting that susceptibility to develop the disease is 
due to the interaction between genetic and environ-
mental factors such as air pollution[20,21]. Being able to 
recognize individuals at high risk to develop COPD 
would help clinicians convincing healthy-smokers to 
quit smoking as well as understanding the genetic ba-
sis of the disease. 
In COPD, the search for circulating blood bio-
markers has mainly focused on plasma/serum proteins 
which are known to be involved in the systemic in-
flammatory response to smoking and subsequent lung 
injury repair[8,15–17,22–26]. In general, cytokines, che-
mokines, metalloproteases (e.g. MMP-9) and highly 
abundant acute phase reactants (e.g., C-reactive pro-
tein, fibrinogen) have been measured and found to 
differentiate COPD patients from healthy controls. 
This directed approach, however, suffers from the fact 
that proteins not previously suspected to be involved 
in the disease are not investigated. As a result, several 
unbiased proteomic studies of plasma and other bio-
logical fluids such as induced sputum, exhaled breath 
condensate, bronchoalveolar lavage or epithelial lining 
fluid, have been performed in order to find novel pro-
tein biomarkers differently expressed in COPD and 
healthy individuals[9,18,20,23]. While many potential 
biomarkers candidates have been pointed out, most of 
them remain at the level of their initial discovery, 
while only few of them reached the level of clinical 
validation. In fact, this “biomarker gap” has consider-
ably increased due to the application of proteomic 
strategies measuring thousands of proteins in groups 
of samples with 5–20 patients/controls per group. 
Considering that COPD is a complex and heteroge-
neous disease, it is unlikely that a single biomarker 
will be sufficient for COPD diagnosis, prognosis or 
treatment evaluation. Therefore, Devanarayan et al. 
stated that proteomic strategies should focus on deli-
vering panels of biomarkers which enable the charac-
terization of the different COPD phenotypes as well as 
reflecting underlying pathological pathways and com-
orbidities[15]. In line, Agusti et al. described a systemic 
inflammatory network pattern (called inflammome) in 
subgroups of COPD patients associated with different 
all-cause mortality and exacerbation frequency[27]. 
Taking all these into consideration, the aim of the 
present review is to advance biomarker development 
in COPD by providing a comprehensive overview of 
protein biomarker candidates which have been eva-
luated in large clinical studies, and have the potential 
of becoming valid and clinically useful biomarkers in 
the near future. 
Methodology and Results 
Our search strategy started with the identification of 
those cohorts with more than 500 subjects and in 
which biological samples have been collected. For this 
search, we employed four complementary databases: 
PubMed, Cochrane Central Register of Controlled 
Trials, Biomarkers Module from the Thompson Reu-
ters IntegritySM database and ClinicalTrials.gov. The 
search strategies followed in each case are summa-
rized in Table 1. In all cases, resulting hits were   
screened, exclusion criteria applied and relevant hits 
selected. Exclusion criteria were: cohorts with less 
than 500 subjects; published only as a congress ab-
stract; cohorts without biological samples collected; 
reviews or literature text-mining publications; studies 
not focusing on COPD but on dyspnea, bronchiectasis, 
asthma, or interstitial lung diseases. Based on these 
criteria we identified 72 cohorts. 52 hits were ex-
cluded because genomic or non-protein biomarkers 
(e.g. desmosine, vitamin D) were investigated, be-
cause hits did not have published results yet, or due to 
double hits in the four different databases. In this way 
20 relevant cohorts remained (Table 2). Subsequently, 
we used PubMed to search for publications reporting 
protein biomarkers from these cohorts, using the  
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Table 1. Search strategy for COPD cohorts (>500 subjects, biolog-
ical samples collected) 
Database Search rules 
PubMed copd[Title] AND cohort [all fields] 
Cochrane Central Re-
gister of Controlled 
Trials  
#1  copd and biomarker 
#2  copd and protein 
#3  copd and serum 
#4  copd and plasma 
#5  copd and sputum 
#6  copd and urine 
#7  copd and bal 
#8  copd and elf 
#9  {or #1–#8} 
Thompson Reuters 
IntegritySM Biomar-
kers Module  
Indication type: COPD 
Validity: late studies in humans (>500 subjects) 
Type: proteomic 
Substrate: DNA exclusion 
ClinicalTrials.gov Search term: COPD 
Results filtered: 
  -  Trials >500 subjects enrolled 
  -  observational studies 
 
cohort name or the registration number. From those 
publications 39 proteins were identified that may have 
the potential to be relevant biomarkers in COPD 
(Table 3). Following proposed criteria of Sin et al.[2] 
for developing novel biomarkers in COPD this list 
was further reduced by selecting only those proteins 
which showed statistically significant differences be-
tween COPD patients and healthy smokers (Table 4). 
Afterwards this list of 7 prioritized proteins was ex-
amined according the other proposed criteria[2] de-
monstrating: biological plausibility in terms of a role 
in the pathogenesis of COPD, association with clinical 
outcomes, evidence that interventions modify the 
biomarker candidate, and evidence that these changes 
associate with important clinical outcomes. 
COPD Cohorts 
Among the identified cohorts (Table 2), a number were 
observational such as the Bergen COPD study[28,29], 
PROMISE-COPD[30], the BODE study[31], the MESA 
Lung study[32] or ECLIPSE[33]. These studies have dif-
ferent aims covering a wide range of aspects related to 
COPD. PROMISE-COPD aims to investigate whether 
circulating biomarkers might be able to predict ex-
acerbations during the stable phase of the disease and 
the clinical outcome of exacerbations in patients with 
COPD[30]. The BODE study investigated the hypothe-
sis that a multidimensional index (the BODE index) 
allows a better categorization and prediction of dis-
ease outcome (mortality) than FEV1 alone[31]. The 
MESA Lung Study is an ancillary study of the Mul-
ti-Ethnic Study of Atherosclerosis (MESA) with the 
aim of testing the chronic endothelial injury hypothe-
sis of COPD and emphysema, in addition to examin-
ing subclinical cardiopulmonary interactions[32]. EC-
LIPSE is a 3-year longitudinal study with four specific 
aims: (i) definition of clinically relevant COPD sub-
types, (ii) identification of parameters that predict 
disease progression in these subtypes, (iii) examina-
tion of biomarkers that correlate with COPD subtypes 
and may predict disease progression, and (iv) identifi-
cation of novel genetic factors and/or biomarkers that 
both correlate with clinically relevant COPD subtypes 
and predict disease progression[33]. Furthermore, our 
systematic search identified interventional case-con-
trol studies in which different COPD treatments (neu-
trophil elastase inhibitors, long acting beta agonists, 
prophylactic antibiotic treatments, cholesterol lowering 
medication, or corticoidsteroids) were evaluated (NCT-
00949975[34], NCT01110200[35], NCT00132860[36,37], 
NCT01061671[38], NCT00325897[39], EUROSCOP[40]). 
In this category, the Lung Health Study (LHS) is a 
representative example. The objectives of LHS I and 
III were (a) to determine whether an intervention pro-
gram incorporating smoking cessation and the use of 
inhaled ipratropium bromide could slow down the 
decline of lung function and reduce the incidence of 
pulmonary morbidity over a 5-year period of fol-
low-up in persons at high risk for developing COPD, 
and (b) to estimate the effects on lung function due to 
bronchodilators over and above the effects of smoking 
intervention[41]. In LHS II the effect of inhaled corti-
costeroids (triamcinolone) on the annual age-related 
decline in pulmonary function in patients with COPD 
was investigated[42]. 
Furthermore, we identified and selected cohorts 
with focus on different lung diseases in which a rep-
resentative number of COPD patients were recruited. 
These cohorts are the SAPALDIA study and the Euro-
pean Community Respiratory Health Survey (ECRHS). 
SAPALDIA was designed to investigate the health 
effects from long-term exposure to air pollution[43] 
with the aim of assessing the prevalence of bronchial 
asthma, chronic (obstructive) bronchitis and allergic 
conditions in the adult population of Switzerland. An 
additional aim was the identification of potentially 
influencing factors, which could be personal (smoking, 
allergy status, family history, occupation) or environ-
mental (outdoor and indoor pollution, aeroallergens, 
climate)[44]. The ECRHS aimed to estimate the varia-
tion in prevalence of asthma, exposure to risk factors  
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Table 2. Cohorts identified as relevant for COPD 
 Name Abbreviation Registration number 
1 Bergen COPD cohort study − n.a. 
2 Predicting Outcome using systemic Markers In Severe Exacerbations of COPD PROMISE-COPD ISRCTN99586989 
3 Evaluation of COPD to Longitudinally Identify Predictive Surrogate Endpoints ECLIPSE NCT00292552 
4 The longitudinal study BODE cohort of COPD patients − n.a. 
5 Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA MESA-Lung NCT00843271 
6 
 
Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered 
Orally at Three Dose Levels to Patients With COPD on Treatment With Tiotropium 
− 
 
NCT00949975 
 
7 COPD Disease Post-hospitalization Study − NCT01110200 
8 Prophylactic Antibiotic Treatment of Patients With COPD − NCT00132860 
9 Simvastatin Therapy for Moderate and Severe COPD STATCOPE NCT01061671 
10 Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With COPD MACRO study NCT00325897 
11 European respiratory society study on chronic obstructive pulmonary disease EUROSCOP n.a. 
12 Lung Health Study (I and III) LHS I-III, II NCT00000569/568 
13 Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults SAPALDIA n.a. 
14 The European community respiratory health survey ECRHS n.a. 
15 Atherosclerosis Risk in Communities Study ARIC study n.a. 
16 The Malmo preventive project − n.a. 
17 
 
The Copenhagen cohorts (Copenhagen City Heart Study and the Copenhagen General 
Population Study) 
− 
 
n.a. 
 
18 Cohort of outpatients from West China Hospital of Sichuan University − n.a. 
19 The Rotterdam study − n.a. 
20 National Health and Nutrition Examination Survey NAHNES III n.a. 
 
for asthma, and asthma treatment across 25 countries 
from the European Community[45,46]. It is known that 
COPD can have significant overlap with other lung- 
related diseases such as asthma[47], making these co-
horts useful to investigate the performance of COPD 
biomarkers in populations with overlapping syn-
dromes. In this line, cardiovascular disease is a well- 
known COPD co-morbidity which can influence pa-
tient mortality and hospitalization rates[48]. Thus, there 
have been different studies in which protein biomark-
ers have been investigated in subgroups of COPD pa-
tients from cardiovascular disease related cohorts. 
Examples of this are the ARIC study, a prospective 
study to investigate the etiology of atherosclerosis and 
its clinical sequelae and variation in cardiovascular 
risk factors, medical care, and disease by race, sex, 
place, and time[49]; the Malmö Prevention Project, a 
preventive case-finding program for cardiovascular 
risk factors and alcohol abuse in the city of Malmö[50]; 
or the Copenhagen City Heart Study[51], a prospective 
cohort study of individuals aged 20 years and older 
that were randomly selected from the population of 
Copenhagen. 
Finally, general population cohorts with a relevant 
(>500) number of COPD subjects were identified and 
selected including the Copenhagen General Popula-
tion Study[52], the Rotterdam study (prospective cohort 
study targeting cardiovascular, endocrine, hepatic, 
neurological, ophthalmic, psychiatric, dermatological, 
oncological, and respiratory diseases[53–55]), the Nati-
onal Health and Nutrition Examination Survey (cross- 
sectional survey providing an estimation of health and 
nutrition status among a representative group of civi-
lian, noninstitutionalized US residents)[56,57] and the 
Cohort of outpatients from the West China Hospital of 
Sichuan University[58]. 
COPD Protein Biomarkers 
After the identification of relevant cohorts, we sear-
ched for all publications from these cohorts in which 
proteins had been investigated or evaluated as poten-
tial COPD biomarkers (see Table 3 for the list of pro-
teins). All the proteins on this list have been shown or 
suggested to be linked to the pathogenesis of the dis-
ease, an important criterium in the selection of useful 
biomarkers in COPD[2]. Indeed this list reflects the 
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complexity of the underlying pathogenesis of COPD, 
involving inflammation, oxidative stress (e.g., due to 
smoking), the protease/anti-protease imbalance, envi-
ronmental factors (such as exposure to pollutants or 
internal cooking), and genetic predispositions[5,59]. 
Accumulating evidence indicates that chronic inflam-
matory and immune responses play key roles in the 
development and progression of COPD[60,61]. In this 
respect, most of the potential biomarkers included in 
our list are proteins involved in inflammation or the 
immune response such as CRP, IL-6, beta defensin 2, 
among many others[25–27,29,36,37,54,62–74]. One of the 
main causes leading to COPD is chronic smoking 
which exposes the respiratory tract to reactive oxygen 
species, resulting in oxidative stress and injury (which 
in the last instance leads also to inflammation)[59,75]. 
Thus, biomarkers of oxidative stress such as ceru-
lo-plasmin[68] could be used to reflect this characteris-
tic of COPD. Furthermore, one of the main compo-
nents of COPD is emphysema which is caused by an 
imbalance between proteases and anti-proteases re-
sulting in lung parenchymal destruction. Representa-
tive molecules of this process are MMP’s[66,72] in-
volved in the breakdown of the extracellular matrix 
and in tissue remodeling, as well as, VEGF involved 
in angiogenesis and tissue remodeling[72]. Furthermore, 
our protein list comprises lung-specific proteins such 
as SPD and CC-16[76–79]. CC-16 is secreted by 
non-ciliated club cells (formerly known as Clara cells) 
which are mainly present in the respiratory bronchi-
oles and by non-ciliated columnar cells present in the 
small airways. SPD is found in the endoplasmic reti-
culum of type II pneumocytes and in the secretory 
granules of club cells. SPD plays a role in the protec-
tion against viral infections, the clearance of bacteria, 
fungi and apoptotic cells, as well as in inflamma-
tion[80]. Finally, proteins that enable to investigate the 
effect of long-term inhaled corticosteroid therapy on 
bone mineral density (a clinical feature in COPD) 
such as osteocalcin were identified[81,82]. 
 
Table 3. Proteins investigated as potential COPD biomarkers within relevant COPD cohorts 
Protein name Abbreviation ID Proposed pathophysiological role Reference 
Adiponectin  Q15848 Anti-inflammatory, anti-diabetic, and anti-atherogenic 
activities 
[64,66,105] 
Beta-defensin-2  A4H1Z7 Role in pulmonary immunity [66] 
Calprotectin  P05109 Anti-infective and anti-inflammatory activities [36] 
Chitinase3-like-1 YKL-40 P36222 Role in cell proliferation and differentiation , inflamma-
tion, extracellular tissue remodeling, and protection 
against apoptosis 
[37] 
Club cell protein 16 CC-16 P11684 Pulmonary inflammatory protein  [22,26,35,78,79,86,91,106,107] 
C-C motif chemokine 18 PARC/CCL-18 P55774 Lung-predominant inflammatory protein. [66,70,72,73,86–88,91,107,108] 
C-C motif chemokine 2 CCL2 P13500 Inflammatory chemokine [66] 
C-X-C motif chemokine 16 CXCL 16 Q9H2A7 Inflammatory chemokine [29] 
Ceruloplasmin  P00450 Protein involved in oxidative stress [68] 
C-reactive protein CRP P02741 Secreted by the liver in response to a variety of inflam-
matory cytokines 
[22,26,27,29,34,38,52,58,64,66, 
69,70,84,86–91,93–95,106–115] 
C-X-C motif chemokine 10 CXCL-10 P02778 Inflammatory chemokine [66] 
E-selectin  P16581 Cell adhesion molecule expressed only on endothelial 
cells activated by cytokines. 
[62] 
Fibrinogen  Q08830, 
P02671, 
P02675 
Coagulation factor [22,26,27,64,66,68,70,83–91,106
–108,111,114,116] 
Fibronectin to CRP ratio  - Coagulation factor/ secreted by the liver in response to a 
variety of inflammatory cytokines 
[69] 
Haptoglobin  P00738 Inflammatory role [68] 
Hepatocyte growth factor  P14210 Systemic inflammation marker [66] 
Interleukin-1 beta IL 1β P01584 Proinflammatory cytokine [67] 
Interleukin-6 IL 6 P05231 Inflammatory interleukin [22,26 
27,34,58,64,66,67,70,72,84,86,9
1,95,107,111,114,115] 
Interleukin-8 IL 8 P10145 Inflammatory interleukin [22,26,27,34,66,70,72,84,86,91, 
107,115] 
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Protein name Abbreviation ID Proposed pathophysiological role Reference 
Interleukin-12 subunit beta IL-12β P29460 Inflammatory interleukin [66] 
Pro-interleukin-16 IL 16 Q14005 Inflammatory interleukin [72] 
Leptin  P41159 Role in lung maturation and development [64] 
Leukotriene A-4 hydrolase  P09960 Inflammatory marker [74] 
Mannose binding lectin MBL P11226 Collectin involved in host defense against infection [63,117] 
Neutrophil collagenase MMP-8 P22894 Breakdown of extracellular matrix involved in tissue 
remodeling 
[66] 
Matrix metalloproteinase-9 MMP-9 P14780 Breakdown of extracellular matrix involved in tissue 
remodeling 
[66,72] 
Monocyte chemoattractant 
protein 
MCP-1/CCL2 P13500 Chemokine regulating migration and infiltration of 
monocytes/macrophages 
[72,112] 
Myeloperoxidase MPO P05164 Cytotoxic protein used by neutrophils to kill bacteria 
and other pathogens 
[66,71] 
Neutrophil gelatinase asso-
ciated lipocalin 
NGAL P80188 Inhibition of bacterial growth and enhancement of ma-
trix degradation 
[113,118] 
Orosomucoid AGP1 P02763 Inflammatory marker [68] 
Osteocalcin  P02818 Indicator of bone mineral density [81,82] 
Osteoprotegrin/Tumor nec-
rosis factor receptor super-
family member 11B 
OPG O00300 Is a decoy receptor for the receptor activator of nuclear 
factor kappa B ligand (RANKL)  
[52,54,119] 
soluble intercellular adhe-
sion molecule 
ICAM-1 P05362 Facilitates leukocyte adhesion and migration across the 
endothelium 
[62] 
Soluble receptor for advan-
ced glycation endproducts 
sRAGE Q15109 The RAGE pathway has been shown to be associated 
with several inflammatory diseases 
[65,91] 
Soluble tumor necrosis fa-
ctor receptor 1 
sTNF-R1 P19438 Proinflammatory cytokine [52,54,119] 
Surfactant protein D SPD P35247 Pulmonary protein involved in innate immunity [22,26,35,70,76,77,80,86,87,91, 
106–108,115] 
Tumor necrosis factor TNFα P01375 Proinflammatory cytokine [22,26,27,34,58,67,70,72,84,86, 
91,107] 
Vascular endothelial growth 
factor 
VEGF P15692 Angiogenic protein/marker of injury and repair [72] 
Vitamin D binding protein DBP Q6LDC6 It binds to vitamin D and its plasma metabolites and 
transports them to target tissues 
[106] 
 
Prioritized COPD Protein Biomarkers 
The list of potential protein biomarkers (Table 3) was 
further reduced by selecting only those that show sta-
tistically significant differences between COPD pa-
tients and healthy smokers (Table 4). This follows the 
recommendation to demonstrate a strong, consistent 
and independent association between a biomarker and 
COPD[2]. In this way, 7 potential proteins remained: 
fibrinogen, CRP, IL-6, PARC, SPD, CC-16, and 
sRAGE. 
Among these proteins, fibrinogen was recently ap-
proved as biomarker for all-cause mortality and ex-
acerbations in COPD subjects. Fibrinogen reflects the 
systemic inflammatory component of COPD, is ele-
vated in COPD patients[27,64,66,83–85], and associated 
with the severity of the disease[27] and FEV1[26]. Fur-
thermore, fibrinogen is associated with increased ex-
acerbation frequency, hospitalization, and mortality in 
COPD patients[66,68,83,86–88], as well as with increased 
cardiovascular events[70,89–91]. Therefore, fibrinogen 
has been accepted by the FDA and COPD Biomarker 
Qualification Consortium (CBQC) for the stratifica-
tion of subjects at risk for hospitalization and mortali-
ty[92]. CRP and IL-6 have also been discussed within 
the CBQC as interesting COPD biomarkers since they 
share many of the features of fibrinogen. CRP and 
IL-6 also reflect the systemic inflammatory compo-
nent of COPD, are increased in COPD patients and 
are associated with important clinical outco-
mes[27,29,52,64,66,70,84,86–90,93–95]. However, the biological 
variability of fibrinogen was lower than for IL-6 or 
CRP, which both display a wide variability in stable 
COPD subjects[66,92]. 
The proteins SPD, CC-16 and PARC are promising 
COPD biomarkers, particularly because they are  
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Table 4. Prioritized proteins able to discriminate between COPD patients and healthy smokers 
Protein name Abbreviation Protein ID Sample Concentration in smoker controls 
Concentration in 
COPD patients 
Significance 
(p-value) Reference 
Club cell protein 16 CC-16 P11684 serum 5.6 (3.1) ng/ml 4.9 (3.4) ng/ml <0.001 [78] 
C-C motif chemokine 18 PARC/CCL-18 P55774 serum 81 (21) ng/ml 105 (26) ng/ml <0.0001 [73] 
C-reactive protein CRP P02741 serum 1.6 (0.8–3.3) µg/ml 3.2 (1.5–7.1) µg/ml <0.001 [27] 
Fibrinogen  
Q08830, 
P02671, 
P02675 
EDTA 
plasma 391 (348–436) mg/dl 448 (388–517) mg/dl <0.001 [27] 
Interleukin-6 IL 6 P05231 serum 0.6 (0.3–1.3) pg/ml 1.5 (0.8–3.1) pg/ml <0.001 [27] 
Soluble receptor for  
advanced lycation  
endproducts 
sRAGE Q15109 serum 1.7 (0.7) ng/ml 1.4 (0.6) ng/ml <0.001 [65] 
Surfactant protein D SPD P35247 Serum 114(76–162) ng/ml 121 (85–174) ng/ml 0.021 [80] 
Concentrations are presened as mean (standard deviation) or median (interquartile range). 
 
highly lung specific. PARC was shown to be elevated 
in COPD patients when compared to healthy smoking 
controls[66,73], and an association between the levels of 
PARC and body mass index, FEV1, BODE index, and 
exacerbation rate was observed[24]. However, in later 
work only a statistically relevant association with the 
BODE index was reconfirmed[72]. Furthermore, ele-
vated blood PARC levels have been associated with a 
higher risk of mortality and exacerbation episodes in 
COPD patients[86–88]. The largest study of PARC in 
COPD to date is the one performed by Sin and 
co-workers[73]. They observed that a 2-week treatment 
with prednisolone associated with reduced PARC le-
vels when compared to placebo. Furthermore, a rela-
tionship of PARC concentrations with a future risk of 
cardiovascular hospitalization and mortality and with 
total mortality was observed. However, some of the 
results of this study were contradictory: in the LHS 
study higher PARC levels were associated with lower 
baseline FEV1 values and increased mortality due to 
cardiovascular disease, while in the ECLIPSE subjects 
the association with FEV1 could not be replicated. 
Finally, PARC levels show wide variability over time 
both in stable COPD patients and healthy controls[66]. 
Thus, additional work is needed to determine the util-
ity of this protein as COPD biomarker. 
Amongst the lung specific proteins, SPD and 
CC-16 have proven to be more stable over time than 
PARC which could make them more useful COPD 
biomarkers[66]. SPD is mainly produced in type II 
pneumocytes[96,97] and plays an important role in pul-
monary immune defense[98], making it an interesting 
potential biomarker in COPD. In this respect, poly-
morphisms in the surfactant protein–D gene (SFTPD) 
have been shown to be associated with susceptibility 
to develop COPD and to influence serum concentra-
tions of SPD[22,77]. Furthermore, SPD levels were 
found to be elevated in COPD patients when com-
pared to healthy smoking controls, although no asso-
ciation with COPD severity[80] nor with the rate of 
change in FEV1[26] was observed. SPD has also proven 
to be associated with a higher risk for exacerba-
tions[80,87] and mortality[86] as well as being reduced 
after prednisolone treatment[80]. SPD has different 
isoforms including a nitrosylated and a cleaved 
form[76], however, these modified SPD products asso-
ciate worse with clinical outcomes of COPD than 
non-modified SPD. Although considered a promising 
COPD biomarker, SPD has so far not proven to be a 
reliable prognostic tool requiring further validation of 
the findings observed so far. CC-16 is predominantly 
secreted from non-ciliated club cells and is localized 
in terminal and respiratory bronchial epithelia[99]. Sig-
nificant associations between several single nucleotide 
polymorphisms and circulating levels of CC-16 have 
been identified in genome-wide association studies, 
however, no strong associations between genotypic 
variations, circulating CC16 levels and risk for devel-
oping COPD were observed[22]. CC-16 is decreased in 
COPD patients when compared to healthy smoking 
controls[78] and has been significantly and indepen-
dently associated with the rate of change in FEV1[26]. 
However, CC-16 levels were not significantly asso-
ciated with mortality[86]. Furthermore, changes in CC-16 
levels are not specific to one agent, disease state or 
specific exposure[100]. As CC-16 is likely to be af-
fected by other forms of lung disease the biomarker 
role of CC-16 in COPD is uncertain and additional 
data is required to assess more rigorously its potential 
as surrogate for disease phenotype, severity and/or 
progression. 
sRAGE, the soluble form of the receptor of ad-
Sara Ongay, Frank Klont, Peter Horvatovich, et al. 
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vanced glycation end-products (RAGE), and a mul-
ti-ligand member of the immunoglobulin superfamily 
of cell surface molecules, has been associated with 
several diseases including diabetes mellitus, cardi-
ovascular, and respiratory diseases[101–103]. RAGE is 
expressed in a variety of tissues including the lung. 
However, unlike in other tissues, RAGE is highly ex-
pressed in the lung under normal physiological condi-
tions[101]. Increased expression of RAGE was demon-
strated in the proximal and distal airways of COPD 
patients compared to both smoking and non-smoking 
controls, and these levels correlated positively with 
impaired lung function[104]. sRAGE is the resulting 
product of both alternative splicing (esRAGE) and 
cleavage of membrane-bound RAGE[101,102]. Circulat-
ing levels of sRAGE are decreased in COPD patients 
when compared to healthy smoking controls and ap-
pear to be associated with emphysema independently 
of COPD severity[65]. In addition to the association of 
sRAGE with emphysema, two SNPs in the gene cod-
ing for RAGE (AGER locus) were significantly asso-
ciated with systemic sRAGE levels. These results in-
dicate that sRAGE is a very promising COPD bio-
marker that deserves further investigation in order to 
prove its usefulness in COPD diagnosis, prognosis 
and treatment development. 
It is worth mentioning that all of the described stu-
dies used ligand binding assays (LBAs; mainly ELI-
SA), often from the same supplier, to quantify proteins 
in biological matrices. This bears the risk that forms of 
a given protein that are recognized by the antibody(ies) 
generate signals while others do not, meaning that our 
picture of how these biomarker candidates reflect dis-
ease development is likely incomplete. There is fur-
ther a risk that systematic bias due to cross-reactivity 
of the antibodies with other proteins may affect the 
results. LBAs are generally not suitable to discrimi-
nate between different forms of a protein due to gen-
etic variability (e.g., due to splicing, single amino acid 
variation, different allele distribution) or post-tran-
slational modifications (e.g. cleavage by proteases, 
modifications due to oxidative stress). Alternative 
methodologies based on chemical analysis principles 
such as LC-MS may provide a different, more detailed 
picture of protein heterogeneity with possibly better 
sensitivity and specificity and predictive values for the 
various aspects of COPD.  
Conclusion 
While many protein biomarker candidates have been 
suggested for COPD diagnosis and prognosis, so far 
only fibrinogen has been approved by the FDA for 
some aspects of the disease. Validation of promising 
biomarkers (for example those in Table 4) in well- 
designed studies, taking into account the different 
phenotypes of COPD, is thus urgently needed to re-
duce the gap between initial discovery and clinical 
application. Most of the studies performed so far 
comprise observational cohort and small-sized expe-
rimental studies, while large randomized clinical trials 
(e.g. evaluating changes in biomarkers in relation to 
interventions and clinical outcome) are scarce. Most 
of the current biomarker candidates are not lung-spe-
cific but may reflect the systemic aspects of COPD 
and its associated co-morbidities. There is a need for 
lung-specific biomarkers derived from proteins that 
are either only expressed in the lung (CC-16, SPD), or 
highly over-represented in the lung (RAGE). Because 
of the complexity of COPD, it is not likely that a sin-
gle biomarker will be able to address the different as-
pects (phenotypes) of the disease. In this respect, a 
panel of biomarkers may be needed to guide persona-
lized treatments of COPD patients[27]. 
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